Mangoceuticals Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company was founded on October 7, 2021 and is headquartered in Dallas, TX.

Dallas, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce that it has added serial technology entrepreneur and investor, Aaron Andrew, to its advisory board (the “Advisory Board”).

Mangoceuticals Adds Renowned Tech Entrepreneur and Investor, Aaron Andrew, to Advisory Board

DALLAS, TX, May 18, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is proud to announce that the Company's Co-Founder and CEO, Jacob Cohen, along with the MangoRx family, including Company officials and members of the executive management team, will ring the Nasdaq Closing Bell on Thursday, May 18, 2023.

Mangoceuticals to Ring NASDAQ Stock Market Closing Bell on May 18

DALLAS, TX, May 11, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is excited to announce the launch of its “Some Things Are Better Hard” digital marketing campaign (the “Campaign”).

Mangoceuticals Launches New “Some Things Are Better Hard” Viral Video Ad Campaign

DALLAS, TX / ACCESSWIRE / May 4, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is pleased to announce the appointment of Amanda Hammer as Chief Operating Officer ("COO"). As COO, Hammer will be responsible for helping MangoRx work to scale its operations and expand its presence in the US market.

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Knnate Biopharma

P3 Health Partners Inc

Terawulf

Insiders think these are penny stocks to buy based on recent filings but are they worth the risk? The post 4 Penny Stocks To Buy According To Insiders This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy According To Insiders This Quarter

Utilizes AI powered customer segmentation to determine best customers through analysis of 400+ attributes per customer profile DALLAS, TX / ACCESSWIRE / April 25, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is pleased to announce that it has commenced an online sales campaign with DojoLabs Group, Inc. ("DataDojo"), utilizing their proprietary Customer Data Platform ("CDP"), and an AI powered, deep learning identification, segmentation, and conversion optimization technology, and a database of over 240 million U.S. consumer profiles used to identify and acquire online customers. Per the terms of a consulting agreement entered into with DataDojo on January 3, 2023, MangoRx has been working with DataDojo to design and develop a custom infrastructure to support MangoRx's scalable direct response online sales campaign.

Mangoceuticals, Inc. (MGRX) Commences Online Direct Sales Campaign Utilizing DataDojo AI and Customer Data Platform (CDP)

Aethlon Medical

Nordic American Tankers

Onconova Therapeutics

Tingo Group Inc

Hot penny stocks to watch this week. This is a significant week for earnings, and mega-cap tech names will headline what's sure to be a volatile week. Next week, the action continues with the upcoming Fed meeting and another rate hike decision.

5 Hot Penny Stocks To Watch With The Stock Market Down This Week

Big moves can be seen on a daily basis in the small-cap space. However, the impressive 175% move in Mangoceuticals (NASDAQ: MGRX ) stock certainly has investors scratching their heads right now.

MGRX Stock: What Is Going on With Mangoceuticals Today?

Farmer Bros.

China Jo-Jo Drugstores Holdings

Vital Farms, Inc.

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 4 Risk Off Stocks That Are Preparing To Pump This Month

Webull's active investors can now access Mangoceuticals, Inc profile on the leading mobile-first brokerage platform DALLAS, TX / ACCESSWIRE / April 20, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is pleased to announce it is now participating on the new Webull Corporate Communication services platform. The MangoRx portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing MangoRx's followers with instant notifications regarding corporate content like company news, updates, earnings reports, investor presentations, and more.

Mangoceuticals, Inc. Now Featured on Webull Corporate Communications Service Platform

Successfully Blends Humor and Health in its First Commercial on YouTube Just 5 Months After Launch   DALLAS, TX / ACCESSWIRE / April 18, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is pleased to announce that its commercial, which originally debuted on YouTube in November 2022, has surpassed over 5 million views. "MangoRx is taking a fresh approach to changing the conversation about men's health beginning with our first product offering, Mango," commented Jacob Cohen, CEO and Co-Founder of MangoRx.

Mangoceuticals, Inc.'s Debut Commercial Surpasses 5 Million Views on YouTube

Strengthens Measures to Protect Shareholder Interests through ShareIntel's DRIL-DownTM process. DALLAS, TX / ACCESSWIRE / March 30, 2023 / Mangoceuticals, Inc. ("MangoRx" or the "Company"), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced that it has retained Shareholder Intelligence Services, LLC ("ShareIntel") for a 12-month, full-service agreement to review the trading of the Company's common stock to track, identify and monitor for potential illegal short selling activities and deploy solutions to help combat any such activities.

Mangoceuticals, Inc. Retains ShareIntel - Shareholder Intelligence Services

CCSC Technology International Holdings Ltd

Clean Energy Technologies Inc

Golden Heaven Group Holdings Ltd

Global Mofy Metaverse Ltd

Millennium Group International Holdings Ltd

Ohmyhome Ltd

Four small issuers began trading this past week, joined by one SPAC. Two small IPOs and one direct listing submitted initial filings.

U.S. IPO Weekly Recap: Small Deals Slip Through The IPO Window

DALLAS, TX / ACCESSWIRE / March 23, 2023 / Mangoceuticals, Inc. ("MangoRx" or the "Company") (NASDAQ:MGRX), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced the closing of its initial public offering of 1,250,000 shares of common stock at a public offering price of $4.00 per share. The total gross proceeds of the offering were $5,000,000, prior to deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Mangoceuticals, Inc. Announces Closing of $5 Million Initial Public Offering

Mangoceuticals shares have dropped nearly 10% Thursday, the second straight day of big losses for the men's wellness company after it went public on Tuesday.  Shares of the Dallas-based company debuted at $4.20 Tuesday morning but had dropped to $3.05 by Wednesday's closing bell.

Erectile dysfunction drugmaker Mangoceuticals fails to maintain IPO price

IPO Shares to Commence Trading Today on Nasdaq under Ticker Symbol "MGRX" DALLAS, TX / ACCESSWIRE / March 21, 2023 / Mangoceuticals, Inc. ("MangoRx" or the "Company")(NASDAQ:MGRX), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for a total of $5,000,000 of gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of its common stock at the public offering price of $4.00 per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

Mangoceuticals, Inc. Announces Pricing of Initial Public Offering

Mangoceuticals has filed proposed terms for a $5 million IPO. The firm is seeking to commercialize a product to treat erectile dysfunction.

Mangoceuticals Aims For $5 Million Micro-IPO

News for Mangoceuticals Inc Stock (MGRX)